Versameb CEO Klaas Zuideveld to Present at the RNA Leaders World Congress
- Presentation demonstrates lead therapeutic candidate VMB-100 has the potential to address the unmet medical needs of patients suffering from Stress Urinary Incontinence
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its leadership team will be attending the RNA Leaders World Congress, taking place on the 16-17th March 2022 in Basel, Switzerland, where Chief Executive Officer Klaas Zuideveld will be presenting data on the Company’s mRNA engineering technology and its lead therapeutic candidate, VMB-100.
